ALDH1A1 and lung carcinoma: Fat1 overexpression (70), aerobic exercise (71), nilotinib, erlotinib (72), all-trans retinoic acid (73), itraconazole (74), cryptotanshinone (55), CFTR31 (75), fluorescent interleukin (76), pomegranate (77), ginsenoside Rg3 (78), puerarin 6′′-O-xyloside (79), glycolysis inhibitor PFK158 (67), globulin (80) can reduce expression of ALDH1 and drug resistance in lung cancer, mainly involved NF-κB pathway, Wnt pathway, Src-STAT3 signaling axis, Wnt/β-catenin/STAT3 axis, Akt/c-Myc signaling pathway.